Abstract
Diabetic nephropathy (DN) is one of the most common complications of diabetes and the main cause of end-stage renal disease (ESRD). The inflammatory response plays a key role in the pathological process of DN. As the most deeply studied inflammasome, NLRP3 should not be overlooked in DN. Its abnormal activation accelerates DN progression. In this review, we summarize our understanding of the structural composition and activation factors of the NLRP3 inflammasome. Moreover, the relationship between NLRP3 inflammasome activation, and the potential of the NLRP3 inflammasome as a therapeutic target for DN will also be discussed.
Keywords: NLRP3 inflammasome, diabetic nephropathy (DN), inflammation, structure of the NLRP3, end-stage renal disease (ESRD), DN progression.
Current Medicinal Chemistry
Title:Targeting the NLRP3 Inflammasome in Diabetic Nephropathy
Volume: 28 Issue: 42
Author(s): Ming Yang*, Xi Wang*, Yachun Han, Chenrui Li, Ling Wei, Jinfei Yang, Wei Chen, Xuejing Zhu and Lin Sun*
Affiliation:
- Department of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, China
- Department of Nutrition, Xiangya Hospital, Central South University, Changsha, Hunan, China
- Department of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, China
Keywords: NLRP3 inflammasome, diabetic nephropathy (DN), inflammation, structure of the NLRP3, end-stage renal disease (ESRD), DN progression.
Abstract: Diabetic nephropathy (DN) is one of the most common complications of diabetes and the main cause of end-stage renal disease (ESRD). The inflammatory response plays a key role in the pathological process of DN. As the most deeply studied inflammasome, NLRP3 should not be overlooked in DN. Its abnormal activation accelerates DN progression. In this review, we summarize our understanding of the structural composition and activation factors of the NLRP3 inflammasome. Moreover, the relationship between NLRP3 inflammasome activation, and the potential of the NLRP3 inflammasome as a therapeutic target for DN will also be discussed.
Export Options
About this article
Cite this article as:
Yang Ming *, Wang Xi *, Han Yachun , Li Chenrui , Wei Ling , Yang Jinfei , Chen Wei , Zhu Xuejing and Sun Lin *, Targeting the NLRP3 Inflammasome in Diabetic Nephropathy, Current Medicinal Chemistry 2021; 28 (42) . https://dx.doi.org/10.2174/0929867328666210705153109
DOI https://dx.doi.org/10.2174/0929867328666210705153109 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endothelial Microparticles: Mediators or Markers of Endothelial Cell Dysfunction?
Current Hypertension Reviews Epidemiology of Diabetes Mellitus in the United Arab Emirates
Current Diabetes Reviews Antiretroviral Drugs and The Kidney: Dosage Adjustment and Renal Tolerance
Current Pharmaceutical Design Healing Effects of Curcumin Nanoparticles in Deep Tissue Injury Mouse Model
Current Drug Delivery Treatment of Cardiovascular Calcification in Uremia
Current Vascular Pharmacology Herbal Medicines for Diabetes Management and its Secondary Complications
Current Diabetes Reviews Exosomes: A Role for Naturally Occurring Nanovesicles in Cancer Growth, Diagnosis and Treatment
Current Gene Therapy MRI findings and renal function in patients on lithium therapy
Current Drug Safety Mechanisms for Cardiorenal Protection of SGLT-2 Inhibitors
Current Pharmaceutical Design Therapeutic Angiogenesis: Recent and Future Prospects of Gene Therapy in Peripheral Artery Disease
Current Gene Therapy Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) Agonists on Glycemic Control, Lipid Profile and Cardiovascular Risk
Current Molecular Pharmacology Antidiabetics Interactions with Herbs: A Compressive Review
Current Diabetes Reviews Gold Nanoparticles - Synthesis and Applications in Cancer Management
Recent Patents on Materials Science Quality of Life in Individuals with Diabetic Foot Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Meet Our Editorial Board Member
Current Diabetes Reviews Transient Receptor Potential (TRP) Cation Channels in Diabetes
Current Topics in Medicinal Chemistry Microglia NLRP3 Inflammasomes Activation Involving Diabetic Neuroinflammation in Diabetic Mice and BV2 Cells
Current Pharmaceutical Design Therapeutic Targets for the Prevention of Type 1 Diabetes Mellitus
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design CCL2-CCR2 Signaling in Disease Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets